<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855476</url>
  </required_header>
  <id_info>
    <org_study_id>15/0519</org_study_id>
    <nct_id>NCT02855476</nct_id>
  </id_info>
  <brief_title>HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease</brief_title>
  <acronym>HDClarity</acronym>
  <official_title>HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HDClarity will seek at least 1200 research participants at different stages of Huntington's&#xD;
      disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of&#xD;
      biomarkers and pathways that will enable the development of novel treatments for HD. The&#xD;
      secondary objective is to generate a high quality plasma sample collection matching the CSF&#xD;
      collections, which will also be used to evaluate biomarkers and pathways of relevance to HD&#xD;
      research and development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will attend a screening and sampling visit. During the screening visit,&#xD;
      medical history, and clinical and phenotypic data will be obtained. Participants who meet the&#xD;
      eligibility requirements are willing to continue in the study, will return for a sampling&#xD;
      visit during which ≤20ml CSF and approximately 50ml blood will be collected following an&#xD;
      overnight fast: blood will be obtained via venipuncture and CSF will be obtained via lumbar&#xD;
      puncture using local anaesthetic if required. Some participants may be invited to return for&#xD;
      an Optional Repeat Sampling Visit approximately 4-8 weeks later.&#xD;
&#xD;
      When participants have completed the Initial Sampling Visit, and Optional Repeat Sampling&#xD;
      Visit, if relevant, their participation in HDClarity will be considered completed. However,&#xD;
      participants may be invited to participate in the study multiple times, allowing at least 11&#xD;
      months between Screening Visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CSF samples banked</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The primary aim of HDClarity is the generation of a CSF sample repository to facilitate therapeutic development for HD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Huntingtin protein level in cerebrospinal fluid</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The concentration of mutant and total huntingtin level in CSF will be quantified and its relationship to disease severity assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kynurenine metabolites in cerebrospinal fluid</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The concentration of metabolites of the kynurenine pathway in CSF will be quantified and their relationship to disease severity assessed</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>Early Pre-manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Pre-manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Manifest HD</arm_group_label>
    <description>Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CSF, serum, plasma (participant DNA available via Enroll-HD)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of 1200 male and female participants, aged between 21 and 75 years, inclusive,&#xD;
        will be enrolled in the study. Eligible participants include healthy controls, people who&#xD;
        are in the early pre-manifest and late pre-manifest stage of HD, and people diagnosed with&#xD;
        early HD, moderate HD or advanced HD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All eligible participants:&#xD;
&#xD;
             a. Are 21-75 years of age, inclusive; and b. Are capable of providing informed consent&#xD;
             or have a legal representative authorized to give consent on behalf of the&#xD;
             participant; and c. Are capable of complying with study procedures, including fasting,&#xD;
             blood sampling and lumbar puncture; and d. Are participating in the Enroll-HD study;&#xD;
             and e. Will have had an Enroll-HD visit within two months of the Screening Visit.&#xD;
&#xD;
          2. For the Healthy Control group, participants eligible are persons who meet the&#xD;
             following criteria:&#xD;
&#xD;
             a. Have no known family history of HD; or b. Have known family history of HD but have&#xD;
             been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD&#xD;
             (CAG &lt; 36).&#xD;
&#xD;
          3. For the Early Pre-manifest HD group, participants eligible are persons who meet the&#xD;
             following criteria:&#xD;
&#xD;
             a. Do not have clinical diagnostic motor features of HD, defined as Unified&#xD;
             Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score &lt; 4; and b. Have&#xD;
             CAG expansion ≥ 40; and c. Have burden of pathology score, computed as (CAG - 35.5) ×&#xD;
             age, &lt; 250.&#xD;
&#xD;
          4. For the Late Pre-manifest HD group, participants eligible are persons who meet the&#xD;
             following criteria:&#xD;
&#xD;
               1. Do not have clinical diagnostic motor features of HD, defined as Unified&#xD;
                  Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score &lt; 4; and&#xD;
&#xD;
               2. Have CAG expansion ≥ 40; and&#xD;
&#xD;
               3. Have burden of pathology score, computed as (CAG - 35.5) x age, ≥ 250.&#xD;
&#xD;
          5. For Early Manifest HD group, participants eligible are persons who meet the following&#xD;
             criteria:&#xD;
&#xD;
               1. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic&#xD;
                  Confidence Score = 4; and&#xD;
&#xD;
               2. Have CAG expansion ≥ 40; and&#xD;
&#xD;
               3. Have Stage I or Stage II HD, defined as UHDRS Total Functional Capacity (TFC)&#xD;
                  scores between 7 and 13 inclusive.&#xD;
&#xD;
          6. For Moderate Manifest HD group, participants eligible are persons who meet the&#xD;
             following criteria:&#xD;
&#xD;
               1. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic&#xD;
                  Confidence Score = 4; and&#xD;
&#xD;
               2. Have CAG expansion ≥ 40; and&#xD;
&#xD;
               3. Have Stage III HD, defined as UHDRS TFC scores between 3 and 6, inclusive.&#xD;
&#xD;
          7. For Advanced Manifest HD group, participants eligible are persons who meet the&#xD;
             following criteria:&#xD;
&#xD;
               1. Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic&#xD;
                  Confidence Score = 4; and&#xD;
&#xD;
               2. Have CAG expansion ≥ 40; and&#xD;
&#xD;
               3. Have Stage IV HD, defined as UHDRS TFC scores between 0 and 2, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. For all groups, participants are ineligible if they meet any of the following exclusion&#xD;
        criteria:&#xD;
&#xD;
          1. Use of investigational drugs or participation in a clinical drug trial within 30 days&#xD;
             prior to Sampling Visit; or&#xD;
&#xD;
          2. Current intoxication, drug or alcohol abuse or dependence; or&#xD;
&#xD;
          3. If using any medications or nutraceuticals, the use of inappropriate (e.g., non&#xD;
             prescribed) or unstable dose within 30 days prior to Sampling Visit; or&#xD;
&#xD;
          4. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment&#xD;
             of the Site Principal Investigator, to impair participant's ability to complete study&#xD;
             procedures, or likely to reduce the utility of the samples and data for the study of&#xD;
             HD; or&#xD;
&#xD;
          5. Needle phobia, frequent headache, significant lower spinal deformity or major surgery;&#xD;
             or&#xD;
&#xD;
          6. Antiplatelet or anticoagulant therapy within the 14 days prior to Sampling Visit,&#xD;
             including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin,&#xD;
             dabigatran, rivaroxaban and apixaban; or&#xD;
&#xD;
          7. Clotting or bruising disorder; or&#xD;
&#xD;
          8. Screening blood test results more than 10% outside the lab's normal range for the&#xD;
             following: white cell count, neutrophil count, lymphocyte count, hemoglobin (Hb),&#xD;
             platelets, prothrombin time (PT) and activated partial thromboplastin time (APTT), or&#xD;
             any combination of blood test results that the Site Principal Investigator deems to be&#xD;
             of clinical significance; or&#xD;
&#xD;
          9. Screening blood test results for C-reactive protein (CRP)&gt;2× upper limit of normal; or&#xD;
&#xD;
         10. Predictable non-compliance as assessed by Site Principal Investigator; or&#xD;
&#xD;
         11. Inability or unwillingness to undertake any of the study procedures; or&#xD;
&#xD;
         12. Exclusion during history or physical examination, final decision to be made by the&#xD;
             Site Principal Investigator; including but not limited to:&#xD;
&#xD;
        i. any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or&#xD;
        ii. any reason to suspect new focal neurological lesion, e.g. new headache, optic disc&#xD;
        swelling, asymmetric focal long tract signs; or iii. any other reason that, in the clinical&#xD;
        judgment of the Site Principal Investigator, it is felt that lumbar puncture performed per&#xD;
        this protocol and associated manuals is unsafe without brain imaging.&#xD;
&#xD;
        m. Serious Adverse Event (SAE) related to study procedures during or following any previous&#xD;
        HDClarity Sampling Visit (if applicable), or SAE related to any other lumbar puncture in&#xD;
        the previous 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward J Wild, MA, MB BChir, MRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna Schubert, PhD</last_name>
    <email>hdclarity-cc@enroll-hd.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail Owen, PhD</last_name>
    <phone>+44 1273 640 688</phone>
    <email>g.owen@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ortiz</last_name>
      <phone>303-867-5473</phone>
      <email>kortiz@kumarneuro.com</email>
    </contact>
    <investigator>
      <last_name>Rajeev Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Koppel</last_name>
      <phone>202-687-1525</phone>
      <email>ek875@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Karen Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kia Ultz</last_name>
      <phone>410-955-1349</phone>
      <email>kcarte23@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jee Bang, MPH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine O' Neill</last_name>
      <phone>336-716-8611</phone>
      <email>coneill@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Francis Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Sims</last_name>
      <phone>832-325-7107</phone>
      <email>jamie.sims@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Furr-Stimming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, The Centre for Huntingtons Disease</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Adurogbangba</last_name>
      <phone>604-822-4872</phone>
      <email>madurogbangba@cmmt.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Blair Leavitt, MD, CM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Movement Disorders</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hela Jerbi</last_name>
      <phone>+49 731-500-63080</phone>
      <email>hela.jerbi@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Jan Lewerenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Josef And Elisabeth Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Kaminski</last_name>
      <email>b.kaminski@klinikum-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Carsten Saft</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pia-Marie Pryssok</last_name>
      <phone>09131-85-44751</phone>
      <email>pia-marie.pryssok@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Winkler Jurgen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Huntington Institute</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svenja Aufenberg</last_name>
      <phone>+49-251-788-788-0</phone>
      <email>svenja.aufenberg@ghi-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Reilmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Nanetti</last_name>
      <phone>(+)39 0223942519</phone>
      <email>lorenzo.nanetti@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Mariotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lega Italiana Ricera Huntington</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Consuelo Ceccarelli</last_name>
      <email>consuelo.ceccarelli@lirh.it</email>
    </contact>
    <investigator>
      <last_name>Ferdinando Squitieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Psychiatry and Neurology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Dusza-Rowińska</last_name>
      <phone>+48 698250623</phone>
      <email>m.dusza.rowinska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Grzegorz Witkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Barrionuevo</last_name>
      <phone>+34 649 14 23 60</phone>
      <email>CIzquierdo@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Jamie Kulisevsky, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wells</last_name>
      <phone>01392408181</phone>
      <email>Robert.wells2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tim Harrower, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Bannister</last_name>
      <phone>0141 232 7600</phone>
      <email>helen.bannister@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Matthew Sheridan, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Huntingtons Disease Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2 FG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer De Souza</last_name>
      <phone>0121 301 2363</phone>
      <email>jennifer.desouza@bsmhft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hugh Rickards, MB, ChB, MSc, FRCPsych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Andresen</last_name>
      <phone>01223 331141</phone>
      <email>kera2@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Roger Barker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF24 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Johnson</last_name>
      <phone>02920746394</phone>
      <email>alison.johnson@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anne Rosser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fife Health Board - Whyteman's Brae Hospital</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY1 2ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fleur Davey</last_name>
      <phone>01383 623623</phone>
      <email>fleurdavey@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Robert Thompson, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Callum Schofield</last_name>
      <phone>0113 39 24679</phone>
      <email>callum.schofield@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jeremy Cosgrove, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Clyne, BSc MSc</last_name>
      <email>andrea.clyne@thewaltoncentre.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rhys Davies, MA BM BCh PhD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's University Of London</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Goff</last_name>
      <phone>0208 725 5375</phone>
      <email>sally.goff@nihr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Nayana Lahiri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Gallehawk</last_name>
      <phone>01865 234892</phone>
      <email>stephanie.gallehawk@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Richard Armstrong, MA, PhD, BMBCh, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Plymouth NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 5FP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Patrick</last_name>
      <phone>01752 439636</phone>
      <email>abigail.patrick1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Daniel Lashley, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hdclarity.net</url>
    <description>Study website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College, London</investigator_affiliation>
    <investigator_full_name>Edward Wild</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The cerebrospinal fluid (CSF) and plasma samples collected in this study will be the basis of future biomarker analysis studies. A Scientific Advisory Committee which will decide how the samples will be analysed.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://hdclarity.net/study-information/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://hdclarity.net/study-information/</doc_url>
      <doc_comment>Draft informed consent form, not yet approved by an Institutional Review Board for clinical use</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02855476/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

